Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...